We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2021 to May 2024
By Michael Dabaie
AstraZeneca said its Bydureon BCise, or exenatide extended-release, was approved in the U.S. for the treatment of type 2 diabetes in pediatric patients ages 10 years and older.
The U.S. Food and Drug Administration approval was supported by the results of the BCB114 Phase III trial in youth with type 2 diabetes. which showed on top of standard of care exenatide extended-release significantly improved glycemic control compared to placebo in pediatrics.
Bydureon BCise was first approved in the U.S. in October 2017 as a once-weekly single-dose autoinjector device to improve glycemic control for adults with type 2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise. It was also approved for use in the European Union in August 2018.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 23, 2021 08:26 ET (12:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
